Fexuprazan Dosage and Clinical Considerations

Introduction to Fexuprazan

• Fexuprazan is a potassium-competitive acid blocker (P-CAB) with an acid-stable formulation that doesn't require enteric coating, is not a prodrug, has a longer half-life, can be taken regardless of meal timing, reaches maximal acid suppression within 1 day, and is not affected by CYP2C19 genetic polymorphisms, as noted in the context of its pharmacological advantages over traditional proton pump inhibitors (PPIs) 1

Dosing and Clinical Guidelines

• The American Gastroenterological Association (AGA) notes that P-CABs should generally not be used as first-line therapy for peptic ulcer disease unless PPI therapy has failed 2
• Fexuprazan may be considered as second-line therapy after failure of twice-daily PPI therapy in patients with documented acid-related reflux, according to guidelines for managing refractory cases 3, 4
• The use of fexuprazan as first-line therapy is generally not recommended for non-erosive GERD or uninvestigated heartburn symptoms, as well as for mild erosive esophagitis (LA grade A/B), due to its potential as a second-line option 3
• Fexuprazan is not recommended as first-line treatment for peptic ulcer disease, highlighting the need for PPI therapy as the initial approach 2

Cost and Safety Considerations

• Cost considerations indicate that P-CABs like fexuprazan are typically more expensive than PPIs, which may impact cost-effectiveness as first-line therapy, emphasizing the need for careful consideration in treatment decisions 3, 4
• The safety profile of fexuprazan appears comparable to PPIs in short-term studies, but long-term safety data are more limited, necessitating ongoing evaluation and monitoring 1
• Serum gastrin levels may be elevated to higher levels with P-CABs compared to PPIs, a factor to consider in the management of patients on these medications 1

Fexuprazan for Gastroesophageal Reflux Disease (GERD) Treatment

Introduction to Fexuprazan Use

• The American Gastroenterological Association recommends starting with standard PPI therapy for 4-8 weeks as the initial approach for GERD patients with heartburn, regurgitation, or non-cardiac chest pain without alarm symptoms 5, 6
• PPIs remain the preferred first-line treatment due to their proven efficacy and significantly lower cost compared to potassium-competitive acid blockers (P-CABs) like fexuprazan 7

First-Line and Second-Line Treatment Recommendations

• The American College of Gastroenterology suggests escalating to twice-daily PPI if there is an inadequate response to once-daily dosing 5, 6
• Fexuprazan may be considered only after documented failure of twice-daily PPI therapy in patients with confirmed acid-related reflux 7
• The guideline recommends considering fexuprazan for patients with severe erosive esophagitis (LA grade C/D) who have failed standard PPI therapy 7, 8

Specific Clinical Scenarios for Fexuprazan

• Fexuprazan can be used as a therapeutic option for healing and maintenance in patients with severe erosive esophagitis (LA grade C/D), though it's not clearly superior to double-dose PPIs 8
• The American Gastroenterological Association suggests using fexuprazan for PPI treatment failures with confirmatory GERD evidence, including LA grade B or greater erosive esophagitis, biopsy-proven Barrett's esophagus, peptic stricture, or ambulatory reflux monitoring showing distal esophageal acid exposure >6% 8

Cost Considerations

• The high cost of fexuprazan compared to PPIs is a significant factor in reserving it for second-line therapy 7
• Even modest clinical superiority of fexuprazan may not justify the higher cost as first-line therapy 7